Standigm Company

Standigm is a workflow AI-driven drug discovery company. Standigm has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Founded in 2015, the company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing.
Technology: Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Pharmaceutical
Industry: Early drug discovery, Drug Repurposing
Headquarters: Seoul, Seoul-t'ukpyolsi, South Korea
Founded Date: 2015-05-04
Employees Number: 101-250
Funding Status: Late Stage Venture
Investors Number: 15
Total Funding: 71240000
Estimated Revenue: $1M to $10M
Last Funding Date: 2021-06-30
Last Funding Type: Series D

Visit Website
business@standigm.com
https://www.twitter.com/ebdgroup
Register and Claim Ownership